A liquid phase analysis method for quantitatively detecting isomer content in dipeptides
By using a liquid phase analysis method combining macrocyclic antibiotics and specific mobile phases, the problem of isomer detection in Boc-His(Trt)-Aib-OH dipeptide was solved, and efficient and accurate dipeptide isomer separation and Quantitative testing ensures drug safety and production quality.
Patent Information
- Application Number
- CN202310802696.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-30
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-06-30
AI Technical Summary
There is a lack of analytical methods in the prior art that can accurately detect isomer content in Boc-His(Trt)-Aib-OH dipeptide, which affects the safety of the drug and the quality control of the production process.
Macrocyclic antibiotics are used as chiral selectors, combined with mobile phase composed of water, alcohol and formic acid for liquid phase analysis, and efficient separation and quantitative detection of dipeptides and their isomers are achieved through isometric or gradient elution.
This method achieves the separation degree between dipeptide and isomer to be above 2.0, and has good separation effect on peak and impurities. It has the characteristics of fast and accurate, high selectivity, wide application range, low cost and high sensitivity, and meets the characteristics of drug analysis and detection Requirements to ensure drug safety and production quality.
Smart Images

Figure CN117007704B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to a liquid phase detection and analysis method for quantitatively detecting the content of dipeptide isomers. Background Art
[0002] Semaglutide is a long-acting GLP-1 analog developed by Nove Nordisk. It is produced by yeast through genetic recombination technology and only requires subcutaneous injection once a week. As one of the representative drugs of GLP-1 analogs, semaglutide has been proven in multiple clinical trials to effectively control blood sugar in combination with different oral hypoglycemic drugs, and can help patients lose weight, reduce systolic blood pressure and improve pancreatic β-cell function.
[0003] Boc-His(Trt)-Aib-OH (dipeptide) is a key starting material in the preparation process of semaglutide API, but Boc-His(Trt)-Aib-OH (dipeptide) contains an isomer (enantiomer) impurity Boc-D-His(Trt)-Aib-OH (controlled ≤0.5%) during the synthesis process. Currently, there is no report on an analytical method for detecting the isomer content in Boc-His(Trt)-Aib-OH (dipeptide) in the prior art.
[0004] Therefore, it is of great prospect and significance to develop a simple, rapid, accurate, widely applicable, low-cost and highly sensitive method for detecting the isomer content of dipeptides composed of one chiral amino acid and one achiral amino acid, especially Boc-His(Trt)-Aib-OH, so as to accurately and quantitatively detect the isomer content in process products or raw materials in the process to ensure the safety of drugs and quality control in the production process. Summary of the invention
[0005] The purpose of the present invention is to provide a liquid phase analysis method for quantitatively detecting the isomer content in a dipeptide composed of a chiral amino acid and a non-chiral amino acid. The specificity, linearity, repeatability, accuracy, quantitative limit and detection limit of this method all meet the requirements of drug analysis and detection, and it has the characteristics of rapidity, accuracy, high selectivity, wide application range, low cost and high sensitivity.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] A liquid phase analysis method for quantitatively detecting the isomer content in a dipeptide, wherein the liquid phase analysis method uses a macrocyclic antibiotic as a chiral selector and is eluted with a mobile phase consisting of water, alcohol and formic acid. The dipeptide consists of an amino acid containing a chiral α-carbon atom and an amino acid containing an achiral α-carbon atom.
[0008] As one embodiment of the present invention, the amino acid containing a chiral α-carbon atom is selected from the natural amino acids of histidine, alanine, arginine, aspartic acid, asparagine, cysteine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine or derivatives of the above natural amino acids. The amino acid containing a non-chiral α-carbon atom is selected from amino acids without chiral carbon atoms such as glycine (natural amino acid), 2-aminoisobutyric acid (Aib, non-natural amino acid or synthetic amino acid), 2,2-diethylglycine, azaalanine and azaglycine.
[0009] As an embodiment of the present invention, the side chain, N-terminal amino group or C-terminal hydroxyl group of the amino acid of the chiral α-carbon atom and / or the amino acid of the achiral α-carbon atom may not contain a protecting group, or may be further connected with a protecting group to form various straight chain and branched chain variants. The protecting group of the side chain or N-terminal amino group of the amino acid may be 9-fluorenylmethyloxycarbonyl Fmoc, tert-butyloxycarbonyl Boc, benzyloxycarbonyl Cbz, trityl Trt, tert-butyl tBu, etc.; the C-terminal hydroxyl group of the amino acid may be substituted by an alkyl group (such as methyl, ethyl, etc.).
[0010] As an embodiment of the present invention, the dipeptide is His-Aib-OH, Boc-His-Aib-OH, His(Trt)-Aib-OH, Boc-His(Trt)-Aib-OH, His-Gly-OH, Boc-His-Gly-OH, His(Trt)-Gly-OH or Boc-His(Trt)-Gly-OH, etc.
[0011] As an embodiment of the present invention, the macrocyclic antibiotic CSPs can be selected from vancomycin (Chirobiotic V), teicoplanin (Chirobiotic T), aglycones of teicoplanin (Chirobiotic TAG) and / or ristocetin A (Chirobiotic R), etc. These macrocyclic antibiotic chiral selectors (belonging to glycopeptides) have a common heptapeptide aglycone core, and the aromatic groups on the core are cross-linked to form a basket-like structure, with a shallow chamber on the structure for forming an inclusion complex and a sugar group fixed on the surface. For example, vancomycin includes 1 sugar part and 3 inclusion cavities; teicoplanin includes 3 sugar groups and 4 inclusion cavities; ristocetin A includes 6 sugar groups and 4 inclusion cavities. It is precisely because of the structural specificity of macrocyclic antibiotic chiral selectors and the enantioselectivity generated by multiple chiral centers that multiple potential possibilities are provided for the occurrence of enantioselective binding, and this property is also the source of the enantioselectivity of many chemical molecules. Among them, Chirobiotic T has better enantiomeric separation ability for amino alcohols, underivatized natural amino acids, synthetic amino acids (such as N-derivatized) and (di)peptides.
[0012] As an embodiment of the present invention, the alcohol in the mobile phase can be selected from one or more of methanol, ethanol, and isopropanol, preferably isopropanol or ethanol, and further preferably isopropanol, because isopropanol has a better separation degree between dipeptides and dipeptide isomers than ethanol or methanol.
[0013] As an embodiment of the present invention, the mass proportion of formic acid in the mixed solvent of water and alcohol can be selected to be 0.001% to 0.5%, preferably 0.001% to 0.1%, and further preferably 0.0016% to 0.02%. Within this range, the separation degree of dipeptide and dipeptide isomers can be better guaranteed, and under the separation conditions of the present invention, formic acid can make the peak shape sharper relative to acetic acid.
[0014] As an embodiment of the present invention, the mass ratio of water to alcohol is 1:10 to 10:1, preferably 1:4 to 3:2.
[0015] As an embodiment of the present invention, the mass ratio of water, alcohol and formic acid is a key variable for controlling enantioselectivity. When the mass ratio of formic acid in a mixed solvent of water and alcohol is 0.02%, the mass ratio of water and alcohol solvent is preferably 60:40 to 50:50. Within this mass ratio range, the separation degree of dipeptide and dipeptide isomers can be maintained above 2.0; however, outside the mass ratio range of 60:40 to 50:50, especially with the increase of alcohol solvent, the separation degree of dipeptide and dipeptide isomers gradually decreases to below 2.0. By reducing the mass ratio of formic acid in a mixed solvent of water and alcohol, such as 0.0016% or 0.002%, even if the mass ratio of water and alcohol solvent is reduced, such as reaching 20:80 or 16:84, the separation degree of dipeptide and dipeptide isomers is still maintained above 2.0.
[0016] As a preferred embodiment of the present invention, the mass ratio of water, alcohol solvent and formic acid is 50:50:0.02, and further preferably the mass ratio of water, isopropanol and formic acid is 50:50:0.02 (separation degree is 2.4) or the mass ratio of water, ethanol and formic acid is 50:50:0.02 (separation degree is 2.2) or the mass ratio of water, ethanol and formic acid is 60:40:0.02 (separation degree is 2.3) or the mass ratio of water, ethanol and formic acid is 200:800:0.02 (separation degree is 2.3) or the mass ratio of water, ethanol and formic acid is 160:840:0.016 (separation degree is 2.2). Under the above mobile phase conditions, the dipeptide and dipeptide isomer peaks are well separated and have good peak shapes. In particular, when the mass ratio of water, isopropanol and formic acid was 50:50:0.02, the separation degree of dipeptide and dipeptide isomers reached 2.4, the impurity separation effect was good, and the chromatographic system operation time was short, not exceeding 20 minutes.
[0017] As an embodiment of the present invention, the flow rate of the mobile phase is 0.5-1.0 ml / min, preferably 0.7 ml / min.
[0018] As an embodiment of the present invention, the elution mode of the mobile phase is isocratic elution or gradient elution, and isocratic elution which is more convenient to operate is preferred.
[0019] As an embodiment of the present invention, the column temperature of the chromatographic column is 20-45° C. As the column temperature increases, the baseline before the dipeptide peak rises more seriously, so the column temperature is preferably 25° C.
[0020] As an embodiment of the present invention, the injection solution concentration is 0.5-1.0 mg / ml, and the injection volume is 5-20 μl. When the solution concentration is 0.5 mg / ml and the injection volume is 20 μl, the sample is slightly overloaded, the baseline before the dipeptide peak is partially raised, and it is higher than the baseline after the dipeptide isomer peak, which will cause the impurity result to be larger; when the solution concentration is 0.5 mg / ml and the injection volume is 10 μl, the sensitivity is low, and the low concentration response cannot meet expectations; when the solution concentration is 0.75 mg / ml and the injection volume is 10 μl, the sensitivity and response are both better.
[0021] As an embodiment of the present invention, considering that the dipeptide and the dipeptide isomers are terminal absorption, according to the ultraviolet full wavelength scanning results, the detection wavelength can be selected as UV 214nm.
[0022] As an embodiment of the present invention, the operating time can be selected to be 15 to 40 minutes, preferably 20 minutes.
[0023] The advantages of the analysis and detection method of the present invention are: providing a liquid phase analysis method for quantitatively detecting the isomer content in a dipeptide composed of a chiral amino acid and a non-chiral amino acid at the same time, the liquid phase analysis method uses a macrocyclic antibiotic as a chiral selector, and is eluted by a mobile phase composed of water, alcohol and formic acid. The specificity, linearity, repeatability, accuracy, quantitative limit and detection limit of this method all meet the requirements of drug analysis and detection, and have the characteristics of rapidity, accuracy, high selectivity, wide application range, low cost and high sensitivity. The analysis method of the present invention can make the separation degree of dipeptide and dipeptide isomers better, reaching more than 2.0, and the peak shape and impurity separation effect are better. The method of the present invention can accurately and quantitatively detect the isomer content in the process product or raw material drug in the process, ensure the safety of the drug and the quality control in the production process, and has good application prospects and important significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figures 1 to 12 This is a chromatogram obtained based on mobile phases #1 to 12 in Example 1.
[0025] Fig.13 This is the chromatogram obtained according to Example 2.
[0026] Fig.14 This is a dipeptide linear result diagram obtained according to Example 4.
[0027] Fig.15 This is a linear result diagram of dipeptide isomers obtained according to Example 4.
[0028] Figures 16 to 18 These are chromatograms of three groups of different mobile phases obtained according to Comparative Example 1.
[0029] Fig.19 It is the chromatogram obtained according to Comparative Example 2. DETAILED DESCRIPTION
[0030] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical scheme of the present invention is now described in detail below in conjunction with specific embodiments, but the protection content of the present invention is not limited to the following embodiments.
[0031] Sample source: The Boc-His(Trt)-Aib-OH dipeptide test sample (purity 99.6%, containing 0.06% Boc-D-His(Trt)-Aib-OH isomer) used in the implementation method was purchased from Xiamen Sinobond Biotechnology Co., Ltd., and the Boc-His(Trt)-Aib-OH dipeptide reference substance (purity 99.5%) and Boc-D-His(Trt)-Aib-OH reference substance (purity 99.2%) dipeptide isomer samples were purchased from Jier Biochemical (Shanghai) Co., Ltd.
[0032] The equipment or other reagents / materials used in the embodiments can be purchased through commercial channels.
[0033] Example 1
[0034] Experimental conditions:
[0035] Equipment: High performance liquid chromatography (HPLC).
[0036] Chromatographic column: CHIROBIOTIC T, 4.6mm*250mm, 5μm.
[0037] Preparation of mobile phase: Isocratic elution was performed with a certain volume ratio of mobile phase. 12 groups of mobile phases were set for screening, as shown in Table 1 and Figures 1 to 12 As shown (the dipeptide is eluted first, and the dipeptide isomer is eluted later). The flow rate of the mobile phase is 0.7 mL / min, the column temperature is 25°C, the injection volume is 10 μL, the detection wavelength is UV 214 nm, and the running time is 20 min.
[0038] Blank solution: acetonitrile.
[0039] Preparation of system suitability solution: Take appropriate amount of dipeptide and dipeptide isomer, dilute with acetonitrile to a solution containing 0.75 mg of dipeptide and 3.75 μg of dipeptide isomer per 1 ml.
[0040] Preparation of test solution: Take an appropriate amount of the test sample and dilute it with acetonitrile to a solution containing 0.75 mg of dipeptide per 1 ml.
[0041] Determination method: Accurately measure the system suitability solution and the test solution and inject them into the liquid chromatograph respectively, and record the chromatogram.
[0042] Table 1 Mobile phase screening process
[0043] # Mobile phase (volume ratio) Separation Atlas 1 Water: methanol: triethylamine and acetic acid = 50:50:1 N / A Figure 1 2 Water: methanol: formic acid = 60: 40: 0.02 N / A Figure 2 3 Water: methanol: formic acid = 50: 50: 0.02 1.8 Figure 3 4 Water: methanol: formic acid = 40: 60: 0.02 1.3 Figure 4 5 Water: methanol: formic acid = 20: 80: 0.02 N / A Figure 5 6 Water: ethanol: formic acid = 200: 800: 0.02 2.3 Figure 6 7 Water: ethanol: formic acid = 160: 840: 0.016 2.2 Figure 7 8 Water: ethanol: formic acid = 60: 40: 0.02 2.3 Figure 8 9 Water: ethanol: formic acid = 50: 50: 0.02 2.2 Fig. 9 10 Water: ethanol: formic acid = 40: 60: 0.02 1.6 Fig.10 11 Water: ethanol: formic acid = 20: 80: 0.02 1.4 Fig.11 12 Water: isopropanol: formic acid = 50:50:0.02 2.4 Fig.12
[0044] The results show that: Figure 1 As shown in the figure, when triethylamine and acetic acid are added to the mobile phase system, the peak shape is not good, and the dipeptide peak on the left crosses with the peak of the dead volume. Figure 2 As shown in the figure, when the volume of water: methanol: formic acid in the mobile phase is 60: 40: 0.02, the peak shape becomes asymmetric, and the elution time exceeds 20 minutes, and the elution is not complete until 30 minutes. Figure 4 , Figure 5 and Fig.11 As shown, when the volume of water:methanol or water:ethanol in the mobile phase = 40:60:0.02 or 20:80:0.02, the resolution of the dipeptide and the dipeptide isomers is less than 2.0.
[0045] like Figure 6 As shown, when the mass ratio of water, ethanol and formic acid is 200:800:0.02, the separation degree of dipeptide and dipeptide isomers is 2.3; Figure 7 As shown, the mass ratio of water, ethanol and formic acid is 160:840:0.016, and the separation degree of dipeptide and dipeptide isomers is 2.2; Figure 8 As shown, the mass ratio of water, ethanol and formic acid is 60:40:0.02, and the separation degree of dipeptide and dipeptide isomers is 2.3; Fig. 9 As shown, the mass ratio of water, ethanol and formic acid is 50:50:0.02, and the separation degree of dipeptide and dipeptide isomers is 2.2; Fig.10 As shown in the figure, the mass ratio of water, isopropanol and formic acid is 50:50:0.02, the separation degree of dipeptide and dipeptide isomers is 2.4, and the separation degree is better. Under the above mobile phase conditions, the peak separation of dipeptide and dipeptide isomers is good, and the peak shape is good. In particular, when the mass ratio of water, isopropanol and formic acid is 50:50:0.02, the separation degree of dipeptide and dipeptide isomers reaches 2.4, and the impurity separation effect is good.
[0046] When the mass proportion of formic acid in the mixed solvent of water and alcohol is 0.02%, the mass ratio of water and alcohol solvent is preferably 60:40 to 50:50. Within this mass ratio range, the separation degree of dipeptide and dipeptide isomers can be maintained above 2.0; however, outside the mass ratio range of 60:40 to 50:50, especially with the increase of alcohol solvent, the separation degree of dipeptide and dipeptide isomers gradually decreases to below 2.0. By reducing the mass proportion of formic acid in the mixed solvent of water and alcohol, such as 0.0016% or 0.002%, even if the mass ratio of water and alcohol solvent is reduced, such as reaching 20:80 or 16:84, the separation degree of dipeptide and dipeptide isomers is still maintained above 2.0.
[0047] Example 2
[0048] On the basis of Example 1, the column temperature was screened and the column temperatures were selected to be 25°C, 30°C, 35°C and 40°C respectively, and the other conditions were the same as in Example 1. Record the chromatogram, specifically compare Fig.13 The results show that the higher the column temperature, the more serious the baseline rise in front of the dipeptide peak, so the analysis method of the present invention is suitable for operation at a column temperature of 25°C.
[0049] Example 3
[0050] On the basis of Example 1, CHIROBIOTIC V (vancomycin) was used to replace CHIROBIOTIC T chiral selector, and the other conditions were the same as Example 1. The separation degree of dipeptide and dipeptide isomer was 1.8, and the peak shape and response were better. The results showed that the chromatographic column was also suitable for the separation of dipeptide and dipeptide isomer.
[0051] Example 4
[0052] With reference to the #12 mobile phase (water: isopropanol: formic acid = 50:50:0.02) used in Example 1, the provided method was methodologically validated for the performance parameters of system suitability, precision, specificity, linearity, limit of quantification, limit of detection, accuracy and range. This validation used Boc-His(Trt)-Aib-OH (dipeptide) as the sample.
[0053] Experimental conditions:
[0054] Equipment: High performance liquid chromatography (HPLC).
[0055] Chromatographic column: CHIROBIOTIC T, 4.6mm*250mm, 5μm.
[0056] Preparation of mobile phase: A mixed solvent of water, isopropanol and formic acid was used as the mobile phase, and the mass ratio of water, isopropanol and formic acid was 50:50:0.02, and isocratic elution was performed. The flow rate of the mobile phase was 0.7 mL / min, the column temperature was 25 °C, the injection volume was 10 μL, the detection wavelength was UV 214 nm, and the running time was 20 min.
[0057] Blank solution: acetonitrile.
[0058] Preparation of system suitability solution: Take appropriate amount of dipeptide and dipeptide isomer, dilute with acetonitrile to a solution containing 0.75 mg of dipeptide and 3.75 μg of dipeptide isomer per 1 ml.
[0059] Preparation of test solution: Take an appropriate amount of the test sample and dilute it with acetonitrile to a solution containing 0.75 mg of dipeptide per 1 ml.
[0060] Determination method: Accurately measure the system suitability solution and the test solution and inject them into the liquid chromatograph respectively, and record the chromatogram.
[0061] (1) System suitability (SST)
[0062] The results were obtained by analyzing the 6-pin system suitability solution, and are shown in Table 2 below.
[0063] Table 2 System suitability results
[0064] name Dipeptide peak area Separation of dipeptide and dipeptide isomer peaks SST-1 34209.426 3.1 SST-2 34188.424 3.1 SST-3 34166.308 3.1 SST-4 34161.695 3.1 SST-5 34215.081 3.1 SST-6 34246.043 3.1 Relative standard deviation RSD 0.1% N / A Acceptable Standards RSD shall not exceed 2% Not less than 1.5 Pass / Fail qualified qualified
[0065] The results show that the RSD of the dipeptide peak area in the 6-shot system suitability solution meets the acceptable standard of no more than 2%; the separation between the dipeptide and dipeptide isomer peaks meets the acceptable standard of no less than 1.5. Therefore, the system suitability results of the analytical method of the present invention meet the requirements.
[0066] (2) Precision
[0067] The precision of an analytical method refers to the degree of consistency of the results obtained by using the analytical method to determine the uniformity of the test sample multiple times. The precision of an analytical method is demonstrated by measuring repeatability.
[0068] The repeatability of the method was evaluated by testing 6 parallel prepared test solutions, and the specific results are shown in Table 3. The RSD of the dipeptide isomer content in the 6 test solutions should not be greater than 15%.
[0069] Table 3 Repeatability results
[0070] name Dipeptide isomer content Repeat 1 0.057% Repeat 2 0.064% Repeat 3 0.062% Repeat 4 0.059% Repeat 5 0.060% Repeat 6 0.063% Relative standard deviation RSD 4% Acceptable Standards No more than 15% Pass / Fail qualified
[0071] The results show that the RSD of the dipeptide isomer content in the 6 independently determined test solutions meets the acceptable standard of no more than 15%. Therefore, the analytical method of the present invention has high precision.
[0072] (3) Exclusivity
[0073] Specificity refers to the ability of an analytical method to accurately determine the presence of the substance being measured in the presence of possible substances such as impurities, degradation products, and excipients. Specificity can be expressed in terms of peak purity and resolution.
[0074] The specificity of the analytical method was demonstrated by analyzing the test samples spiked with dipeptide isomers (codes: Spiked 0.5%-1, Spiked 0.5%-2, and Spiked 0.5%-3), 100% concentration of dipeptide and dipeptide isomers (codes: 100%-L-STD and 100%-D-STD), and 50% concentration of dipeptide and dipeptide isomers (codes: 50%-L-STD and 50%-D-STD). The specific results are shown in Table 4.
[0075] Table 4 Specificity results
[0076]
[0077] The results show that the separation degree of dipeptide and dipeptide isomer peaks is not less than 1.5, and the dipeptide and dipeptide isomer peaks are pure. In the test sample labeled with isomers, the separation degree of dipeptide and dipeptide isomer peaks is not less than 1.5; in the 100% concentration of dipeptide and dipeptide isomer, the dipeptide and dipeptide isomer peaks are pure, which meets the requirements. Therefore, the analytical method of the present invention has good specificity.
[0078] (4) Linear
[0079] The linearity of an analytical method refers to the fact that within a certain range, the measurement result of the analyte in the test sample is directly proportional to its concentration or through appropriate mathematical transformation.
[0080] The linearity of the analytical method can be demonstrated by parallelizing several linear solutions. The concentration of dipeptide and dipeptide isomers in each linear solution (μg / ml) is used as the horizontal axis, and the peak area is used as the vertical axis (the average value of several tests). Linear fitting can be performed to obtain a standard linear equation. The regression line generated by the data produces a correlation coefficient (R) of not less than 0.990. The dipeptide linearity results are shown in Table 5 and Fig.14 As shown, the linear results of dipeptide isomers are shown in Table 6 and Fig.15 shown.
[0081] Table 5 Summary of dipeptide linearity results
[0082]
[0083] Table 6 Summary of linear results of dipeptide isomers
[0084]
[0085] The results show that the linearity of the dipeptide concentration in the range of 0.3835 μg / ml to 11.5060 μg / ml (equivalent to the impurity level of 0.05%-1.5%) meets the acceptable standard of a correlation coefficient (R) of not less than 0.990, and the linearity of the dipeptide isomer concentration in the range of 0.3754 μg / ml to 11.2606 μg / ml (0.05%-1.5% impurity level) meets the acceptable standard of a correlation coefficient (R) of not less than 0.990. Therefore, the analytical method of the present invention has good linearity. And the correction factor is obtained by the ratio of the dipeptide isomer to the dipeptide linear equation slope (42803.930 / 39853.362≈1.07), which falls within the range of 0.9-1.1 and does not require correction.
[0086] (5) Linear
[0087] The scope of an analytical method refers to the range of high and low concentrations of the analyte within which the method can produce results with a certain degree of precision, accuracy and linearity.
[0088] The scope of the analytical method was demonstrated by analyzing solutions at the 0.05%, 0.5% and 1.5% levels, with the dipeptide specific results shown in Table 7 and the dipeptide isomer specific results shown in Table 8.
[0089] Table 7 Dipeptide range results
[0090]
[0091] Table 8: Dipeptide isomer range results
[0092]
[0093] The results show that the average recovery rate of each level meets the acceptance standard between 80-120%. The RSD of the recovery rate at each level meets the acceptance standard of not more than 15%, and the correlation coefficient (R) meets the acceptance standard of not less than 0.990. Therefore, it is proved that the range of dipeptide in the analytical method of the present invention is 0.3835μg / ml to 11.5060μg / ml, and the range of dipeptide isomers is 0.3754μg / ml to 11.2606μg / ml.
[0094] (6) Limit of quantification
[0095] The limit of quantitation is the lowest amount of the analyte in the test sample that can be measured with acceptable precision and accuracy under specified experimental conditions.
[0096] The quantitative limit of the analytical method was demonstrated by analyzing six parallel prepared limit of quantitation (LOQ) solutions (dipeptide concentration 0.3835 μg / ml, dipeptide isomer concentration 0.3754 μg / ml, equivalent to 0.05% level). The specific results are shown in Table 9.
[0097] Table 9 Quantitation limit solution test results
[0098]
[0099] The results showed that the signal-to-noise ratio of dipeptides and the signal-to-noise ratio of dipeptide isomers in 6 parallel prepared limit of quantitation solutions met the acceptable standard of not less than 10; the average recovery rate of dipeptides and the average recovery rate of dipeptide isomers met the acceptable standard of 80-120%; the RSD of the average recovery rate of dipeptides and the average recovery rate of dipeptide isomers met the acceptable standard of not more than 15%.
[0100] (7) Detection limit
[0101] The detection limit refers to the lowest amount of the analyte that can be detected in the test sample under specified test conditions, which does not necessarily require quantitative determination.
[0102] The detection limit of the analytical method was demonstrated by analyzing 6 parallel prepared detection limit solutions (dipeptide and dipeptide isomer concentration 0.19 μg / ml, equivalent to 0.025% level), and the specific results are shown in Table 10.
[0103] Table 10 Results of detection limit solutions
[0104] repeat Dipeptide S / N Dipeptide isomers S / N LOD-1 16 8 LOD-2 14 8 LOD-3 14 7 LOD-4 13 7 LOD-5 14 8 LOD-6 13 7 Acceptable Standards Not less than 3 Not less than 3 Pass / Fail qualified qualified
[0105] The results showed that dipeptide and dipeptide isomers could be detected in 6 parallel prepared detection limit solutions, which met the requirements (S / N≥3).
[0106] (8) Accuracy
[0107] The accuracy of an analytical method refers to the degree of closeness between the test results obtained by the method and the true value. The accuracy of an analytical method should be measured within a certain range.
[0108] The accuracy of the analytical method was demonstrated by analyzing the recoveries and RSDs of labeled test samples (the test samples were labeled with three levels of dipeptide isomers, 0.05%, 0.5% and 1.5%, respectively). The specific results are shown in Table 11.
[0109] Table 11 Recovery and RSD of dipeptide isomers
[0110]
[0111] The results show that the average recovery rate of each level meets the acceptance standard between 80-120%. The RSD of the recovery rate at each concentration meets the acceptance standard and shall not be greater than 15%. Therefore, the analytical method of the present invention is accurate.
[0112] Comparative Example 1
[0113] Experimental conditions:
[0114] Equipment: High performance liquid chromatography (HPLC).
[0115] Chromatographic column: CHIRALPAK QD-AX (chiral ion exchanger, with cinchona carbamate as selector, the separation principle is to use the ionized selector to produce ionic interaction between the analyte and the selector with opposite charge), 4.6mm*250mm, 5μm. Preparation of mobile phase: methanol, glacial acetic acid and triethylamine are used as mobile phases, the mass ratio of methanol, glacial acetic acid and triethylamine is 100:2:0.2, and isocratic elution is performed. The flow rate of the mobile phase is 0.5mL / min, the column temperature is 25℃, the injection volume is 10μL, 30μL and 100μL respectively, the detection wavelength is UV 214nm, and the running time is 20min.
[0116] Blank solution: methanol.
[0117] Preparation of system suitability solution: Take appropriate amount of dipeptide and dipeptide isomer, dilute with methanol to a solution containing 0.5 mg of dipeptide and dipeptide isomer per 1 ml.
[0118] Determination method: Accurately measure the system suitability solution and the test solution and inject them into the liquid chromatograph respectively, and record the chromatogram. Fig.16 shown.
[0119] The results showed that under the chromatographic conditions, when the injection volume was 10 μL or 30 μL, the responses of the dipeptide and dipeptide isomer peaks were low, below 1.0; even if the injection volume was increased to 100 μL, although the response of the main peak increased, there was room for further improvement in the response, and after increasing the injection volume, the separation degree of the dipeptide and dipeptide isomer peaks was 1.5, and the separation degree became worse.
[0120] Further screening of the mobile phase revealed that under the conditions of the CHIRALPAK QD-AX (chiral ion exchanger) column, the peak response was generally low, less than 1.0. When the mobile phase of methanol, glacial acetic acid and diethylamine = 500:5:1 was selected, the chromatographic peak was very prone to bifurcation, as shown in the following example. Fig.17 When the mobile phase of methanol: glacial acetic acid: triethylamine = 500:5:4 is selected, unknown peaks will appear, as shown in the following figure. Fig.18As shown in the figure, the possible reason for the analysis is that the pH of the mobile phase is close to 6.0, which is close to the pKa of the dipeptide. The dipeptide is partially ionized. The two states of the same compound have a tendency to separate under this chromatographic condition, so there are three peaks. When other mobile phase systems are selected, the chromatography method is completely unseparated or the separation degree is ≤1.5. Therefore, this method is not applicable.
[0121] Comparative Example 2
[0122] Experimental conditions:
[0123] Equipment: High Performance Liquid Chromatography (HPLC). Chromatographic column: CHIRALPAK IC (polysaccharide derivative solvent-resistant chiral column, cellulose-tris(3,5-dichlorophenylcarbamate) covalently bonded to the silica gel surface, chiral recognition may come from the chiral centers of multiple glucose units in the molecule, the helical twist of the polymer backbone, and the connection of adjacent polymer chains in the chiral cavity), 4.6mm*250mm, 5μm.
[0124] Four groups of mobile phases were set up for screening (group #1 was acetonitrile:isopropanol = 90:10, group #2 was acetonitrile:isopropanol = 60:40, group #3 was 0.1% trifluoroacetic acid acetonitrile solution:isopropanol = 95:5, and group #4 was n-hexane:isopropanol = 6:40); the flow rate of the mobile phase was 0.5 mL / min, the column temperature was 25°C, the injection volume was 10 μL, the detection wavelength was UV 214 nm, and the running time was 20 min.
[0125] Blank solution: isopropanol.
[0126] Preparation of system suitability solution: Take appropriate amount of dipeptide and dipeptide isomer, dilute with isopropanol to a solution containing 0.5 mg of dipeptide and dipeptide isomer per 1 ml.
[0127] Determination method: Accurately measure the system suitability solution and the test solution and inject them into the liquid chromatograph respectively, and record the chromatogram. The typical spectrum of group #1 is as follows Fig.19 shown.
[0128] The results showed that under the chromatographic column conditions, the above four groups of mobile phases eluted completely unseparated dipeptide and dipeptide isomer peaks, so this method is not applicable.
Claims
1. A liquid phase analysis method for quantitatively detecting the isomer content in dipeptides, Features: The dipeptide is Boc-His(Trt)-Aib-OH, and the isomer is Boc-D-His(Trt)-Aib-OH; the liquid phase analysis method uses CHIROBIOTIC T as a chromatographic column, uses the macrocyclic antibiotic teicoplanin as a chiral selector, the detection wavelength is UV214nm, and the mobile phase composed of water, isopropanol and formic acid is used for isocratic elution, and the mass ratio of water: isopropanol: formic acid is 50:50:0.
02.
2. The liquid phase analysis method according to claim 1, Features: The flow rate of the mobile phase is 0.5-1.0 ml / min, the column temperature of the chromatographic column is 20-45° C., the concentration of the injection solution is 0.5-1.0 mg / ml, the injection volume is 5-20 μl, and the running time is 15-40 min.
Citation Information
Patent Citations
Method for separating and measuring Palonosetron hydrochloride and optical isomers thereof
CN101661019A
Protected amino acid enantiomer detection method
CN111505161A
Novel chiral selectors and stationary phases for separating enantiomer mixtures
WO2009112325A1
